Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV

Table 1 Baseline characteristics of subjects

Subject characteristics	Group I 2002–2005	%	Group II 2005–2007	%	P value
	N = 47		N = 22
Mean age (years)	33.3 ± 7.9		37.8 ± 6.3		0.016
Gender
• Male	44	93.6	22	100
• Female	3	6.4	0	0
HIV diagnosis at hospital	43	91.5	16	72.7	0.064
Prior OI (%)	0	0	0	0
HBV co-infected	2	4.3	2	9.1	0.587
HCV co-infected	38	80.9	15	68.2	0.245
Type of TB
• Pulmonary only	31	66	19	86.4	0.08
• Disseminated	16	34	3	13.6
TB drug susceptibility
• Unknown	18	38.3	7	31.8	0.485
• Pan-sensitive	15	31.9	11	50
• Single drug resistance	7	14.9	3	13.6
• Poly-drug resistance	4	8.5	0	0
• Multi-drug resistance	3	6.4	1	4.5
Mean CD4 lymphocyte count at diagnosis (SD)	204 ± 184.06		164.7 ± 200.9		0.20
• Median CD4 lymphocyte count	132		60
• CD4 ≤ 100 cells/mm³	15		13
• CD4 101–200 cells/mm³	26		9		0.22